SCHEMBL16419738

SCHEMBL16419738

CC(=N)NCCCOc1cccc(-n2cc(-c3cc(OCCCNC(=N)N)cc(-c4cn(-c5cccc(OCCCNC(=N)N)c5)nn4)c3)nn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 2/20 0.41
▸ NFE2L2 Q16236 2/20 0.41
▸ NOTUM Q6P988 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ FAAH O00519 1/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ HSD17B1 P14061 1/20 0.37
▸ HSD17B2 P37059 1/20 0.37
▸ STIM1 Q13586 2/20 0.36
▸ ORAI1 Q96D31 2/20 0.36
▸ STS P08842 2/20 0.36
▸ EGLN1 Q9GZT9 2/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15036884 0.95 KEAP1 (0.42) KEAP1NFE2L2NOTUMCYP1B1FAAH
SCHEMBL16419734 0.92 CYP1B1 (0.47) CYP1B1STIM1ORAI1STSEGLN1
SCHEMBL16419764 0.87 CYP1B1 (0.49) CYP1B1STIM1ORAI1STSEGLN1
SCHEMBL15036886 0.78 KEAP1 (0.48) KEAP1NFE2L2NOTUMCYP1B1HSD17B1
SCHEMBL16419736 0.77 L3MBTL1 (0.40) CYP1B1
SCHEMBL16419740 0.74 L3MBTL1 (0.45) —
SCHEMBL15244877 0.73 KEAP1 (0.55) KEAP1NFE2L2NOTUMHSD17B1HSD17B2
SCHEMBL16605484 0.71 PRSS1 (0.44) HDAC1HDAC2
SCHEMBL15036871 0.71 OGT (0.43) HSD17B1HSD17B2EGLN1HDAC3HDAC1
SCHEMBL15037015 0.71 PRSS1 (0.42) CYP1B1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469616-B2 Cyclic compounds and methods of making and using the same CELLCEUTIX CORPORATION (US) 2016-10-18 — — US disclosed
US-20150031738-A1 CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME UNIVERSITY OF MASSACHUSETTS (US) 2015-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031738-A1 CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MUC1, TLR3, ALG1 KEAP1 1835/4885NFE2L2 4399/4885NOTUM 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback